これだけは知っておいてください！腎臓の診療にすぐに役立つ63のQ＆A

第1章 心腎連関

P.4 掲載の参考文献

1 Rangaswami J, et al. Cardiorenal Syndrome:Classification, Pathophysiology, Diagnosis, and Treatment Strategies:A Scientific Statement From the American Heart Association. Circulation. 2019;139:e840-e878. PMID:30852913.

 

2 Herzog CA. Congestive Heart Failure and Chronic Kidney Disease:The CardioRenal/NephroCardiology Connection. J Am Coll Cardiol. 2019;73:2701-2704. PMID:31146815.

 

3 Kazory A, et al. Cardionephrology:Proposal for a Futuristic Educational Approach to a Contemporary Need. Cardiorenal Med. 2018;8:296-301. PMID:30089281.

 

4 Rangaswami J, et al. Resuscitation for the specialty of nephrology:is cardionephrology the answer? Kidney Int. 2018;93:25-26. PMID:29137816.

 

5 Hatamizadeh P. Introducing Nephrocardiology. Clin J Am Soc Nephrol. 2022;17:311-313. PMID:34893503.

 

6 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

7 Banerjee D, et al. Personalizing heart failure management in chronic kidney disease patients. Nephrol Dial Transplant. 2022;37:2055-2062. PMID:33591313.

 

P.8 掲載の参考文献

1 Damman K, et al. The kidney in heart failure:an update. Eur Heart J. 2015;36:1437-1444. PMID:25838436.

 

2 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

3 Emmens JE, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24:365-374. PMID:34786794.

 

4 He X, et al. Worsening of Renal Function Among Hospitalized Patients With Acute Heart Failure:Phenotyping, Outcomes, and Predictors. Mayo Clin Proc. 2022;97:1619-1630. PMID:36058576.

 

5 Wettersten N, et al. Diuretic Resistance-A Key to Identifying Clinically Significant Worsening Renal Function in Heart Failure? Mayo Clin Proc. 2022;97:1598-1600. PMID:36058571.

 

6 Yamada T, et al. Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. Kidney Int Rep. 2020;5:1486-1494. PMID:32954072.

 

P.10 掲載の参考文献

1 Wettersten N, et al. Diuretic Resistance-A Key to Identifying Clinically Significant Worsening Renal Function in Heart Failure? Mayo Clin Proc. 2022;97:1598-1600. PMID:36058571.

 

2 Mullens W, et al. Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603. PMID:31908120.

 

P.12 掲載の参考文献

1 Cox ZL, et al. Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. Kidney360. 2022;3:954-967. PMID:36128483.

 

2 Cox ZL, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021;42:4468-4477. PMID:34529781.

PubMed

P.14 掲載の参考文献

1 Cox ZL, et al. Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. Kidney360. 2022;3:954-967. PMID:36128483.

 

2 Rao VS, et al. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. J Am Coll Cardiol. 2021;77:695-708. PMID:33573739.

 

3 Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol. 2019;14:1248-1257. PMID:30936153.

 

4 白石泰之. 急性期こそタイムリーな心不全治療を. 週刊医学界新聞. 2022;3485.. https://www.igaku-shoin.co.jp/paper/archive/y2022/3485_04

 

P.18 掲載の参考文献

1 Novak JE, et al. Diuretics in States of Volume Overload:Core Curriculum 2022. Am J Kidney Dis. 2022;80:264-276. PMID:35190215.

 

2 Ellison DH, et al. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377:1964-1975. PMID:29141174.

 

3 Cox ZL, et al. Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. Kidney360. 2022;3:954-967. PMID:36128483.

 

4 Cox ZL, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021;42:4468-4477. PMID:34529781.

PubMed

5 Rao VS, et al. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. J Am Coll Cardiol. 2021;77:695-708. PMID:33573739.

 

P.21 掲載の参考文献

1 Felker GM, et al. Diuretic Therapy for Patients With Heart Failure:JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:1178-1195. PMID:32164892.

 

2 白石泰之. 急性期こそタイムリーな心不全治療を. 週刊医学界新聞. 2022;3485. https://www.igaku-shoin.co.jp/paper/archive/y2022/3485_04

 

3 Girerd N, et al. The lower is not always the better:a more comprehensive understanding of loop diuretics in heart failure. Eur J Heart Fail. 2021;23:1120-1121. PMID:33826210.

 

4 Rohde LE, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy:a double-blind, multicentre, randomized trial. Eur Heart J. 2019;40:3605-3612. PMID:31424503.

 

5 Dauw J, et al. Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy. Eur J Heart Fail. 2021;23:1110-1119. PMID:33641220.

 

6 Okoye C, et al. Discontinuation of Loop Diuretics in Older Patients with Chronic Stable Heart Failure:A Narrative Review. Drugs Aging. 2023;Aug 25. PMID:37620655.

 

P.23 掲載の参考文献

1 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

2 Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386:2024-2034. PMID:35613023.

 

3 Jackson AM, et al. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020;142:1040-1054. PMID:32673497

 

P.28 掲載の参考文献

1 Leehey DJ. Does a patient with a mild decrease in estimated glomerular filtration rate really have a disease? in Nephrology Rounds. Wolters Kluwer, 2016.

 

2 Delanaye P, et al. CKD:A Call for an Age-Adapted Definition. J Am Soc Nephrol. 2019;30:1785-1805. PMID:31506289.

 

3 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

4 Faucon AL, et al. Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney Int. 2019;96:1020-1029. PMID:31477263.

 

5 Mullens W, et al. Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603. PMID:31908120.

 

P.31 掲載の参考文献

1 日本循環器学会/日本心不全学会合同ガイドライン. 2021年 JCS/JHFS ガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021.

 

2 Patel Y, et al. Sodium Intake and Heart Failure. Int J Mol Sci. 2020;21:9474. PMID:33322108.

 

3 Ezekowitz JA, et al. Reduction of dietary sodium to less than 100 mmol in heart failure(SODIUMHF):an international, open-label, randomised, controlled trial. Lancet. 2022;399:1391-1400. PMID:35381194.

 

P.35 掲載の参考文献

1 Mullens W, et al. Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603. PMID:31908120.

 

2 Mullens W, et al. Renal effects of guideline-directed medical therapies in heart failure:a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-619. PMID:35239201.

 

P.39 掲載の参考文献

1 Verma A, et al. SGLT2 Inhibitor:Not a Traditional Diuretic for Heart Failure. Cell Metab. 2020;32:13-14. PMID:32640243.

 

2 Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2(Sodium-Glucose Linked Transporter 2)Inhibitors. Hypertension. 2020;75:894-901. PMID:32114848.

 

3 Verma S, et al. Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. Eur Heart J. 2022;43:2994-2996. PMID:35680380.

 

4 Palmer BF, et al. SGLT2 Inhibition and Kidney Potassium Homeostasis. Clin J Am Soc Nephrol. 2023;Aug 28. PMID:37639260.

 

5 Aklilu AM, et al. Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by Acute Kidney Injury. Kidney 360. 2023;Aug 30. PMID:37644648.

 

6 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

P.41 掲載の参考文献

1 Wiegley N, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection:Is There Room for Real Concern? Kidney360. 2020;3:1991-1993.

 

2 Takeuchi Y, et al. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan:Target trial emulation using a nationwide administrative claims database. Diabetes Obes Metab. 2021;23:1379-1388. PMID:33606891.

 

3 Hall V, et al. Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction. BMJ Case Rep. 2017;May 22. PMID:28536217.

 

2 村川裕二. MR拮抗薬は三英傑-エサキセレノンは家康? 日経メディカル. 2022年4月1日.

 

3 安藤亮. なぜこの患者の血圧は下がらない 難治性高血圧への次なる一手. 週刊日経メディカルPDF版. 2022年9月9日号.

 

4 Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229. PMID:33264825.

 

5 栗原勲. MR拮抗薬と高血圧治療. 日腎会誌. 2022;64:367-372.

 

6 Albakr RB, et al. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia:A Review of the Evidence From Clinical Trials. Am J Kidney Dis. 2023;Jul 28:S0272-6386(23)00743-6. PMID:37517546.

 

7 Epstein M, et al. Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD:Understanding and Mitigating the Risks. Clin J Am Soc Nephrol. 2022;17:455-457. PMID:34853060.

 

P.44 掲載の参考文献

1 Epstein M, et al. Aldosterone, Mineralocorticoid Receptor Activation, and CKD:A Review of Evolving Treatment Paradigms. Am J Kidney Dis. 2022;80:658-666. PMID:36057467.

 

P.47 掲載の参考文献

1 McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl. (2011). 2021;11:35-45. PMID:33777494.

 

2 McDonagh T, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure:putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20:1664-1672. PMID:30311713.

 

3 内田啓子, 日本腎臓学会編. 日本腎臓学会 HIF-PH 阻害薬適正使用に関する recommendation. 日腎会誌. 2020;62:711-716. https://jsn.or.jp/data/HIF-PH_recommendation.pdf

 

4 Beaudoin J, et al. Risk of Infection With Intravenous Iron Infusion. Am Fam Physician. 2022;106(3):Online. PMID:36126002.

 

5 Gangat N, et al. Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis:assessment of risk and need for referral to haematology. Nephrol Dial Transplant. 2023;38:2670-2672. PMID:37468452.

 

P.56 掲載の参考文献

1 Baker M, et al. NSAIDs in CKD:Are They Safe? Am J Kidney Dis. 2020;76:546-557. PMID:32479922.

 

2 田口敏彦ら監修. 疼痛医学. 医学書院, 2020.

 

3 Koncicki HM, et al. Pain Management in CKD:A Guide for Nephrology Providers. Am J Kidney Dis. 2017;69:451-460. PMID:27881247.

 

4 Davison SN. Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure. Clin J Am Soc Nephrol. 2019;14:917-931. PMID:30833302.

 

5 Wagner LA, et al. Patient safety issues in CKD:core curriculum 2015. Am J Kidney Dis. 2015;66:159-169. PMID:25987263.

 

6 Lu E, et al. Opioid Management in CKD. Am J Kidney Dis. 2021;77:786-795. PMID:33500128.

 

7 Zhan M, et al. Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD:Findings From the CRIC(Chronic Renal Insufficiency Cohort)Study. Am J Kidney Dis. 2020;76:184-193. PMID:32317121.

 

8 Novick TK, et al. Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR. Clin J Am Soc Nephrol. 2019;14:1581-1589. PMID:31582462.

 

9 丹波喜一郎. CKMにおける緩和ケアのあり方. 日腎会誌. 2023;65:880-884.

 

10 植村健司. 極論で語る緩和ケア. 丸善出版. 2023.

 

11 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

第2章 腎機能検査

P.60 掲載の参考文献

1 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン2023, 東京医学社, 2023.

 

P.64 掲載の参考文献

1 Sterns RH. Managing electrolyte disorders:order a basic urine metabolic panel. Nephrol Dial Transplant. 2020;35:1827-1830. PMID:32780104.

 

2 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

3 Decaux G, et al. Estimated Daily Urine Volume and Solute Excretion from Spot Urine Samples to Guide the Therapy of Hyponatremia in SIADH. J Clin Med. 2019;8:1511. PMID:31547128.

 

P.66 掲載の参考文献

1 Brown RS. Fractional Excretion of Sodium and Urea are Useful Tools in the Evaluation of AKI:COMMENTARY. Kidney360. 2023;4:e731-e733.

PubMed

2 Abdelhafez M, et al. Diagnostic Performance of Fractional Excretion of Sodium for the Differential Diagnosis of Acute Kidney Injury:A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2022;17:785-797. PMID:35545442.

 

3 Hamadah A, et al. Fractional Excretion of Sodium and Urea are Useful Tools in the Evaluation of AKI:PRO. Kidney360. 2023;4:e725-e727.

PubMed

4 Aron AW, et al. Fractional Excretion of Sodium and Urea are Useful Tools in the Evaluation of AKI:CON. Kidney360. 2023;4:e728-e730.

PubMed

第3章 腎生理

P.68 掲載の参考文献

1 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

P.70 掲載の参考文献

1 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる!南山堂, 2018

 

P.74 掲載の参考文献

1 木戸口慧ら. 腎臓におけるナトリウム調節と高血圧. 日腎会誌. 2022;64:362-366.

 

2 Canaud B, et al. Sodium and water handling during hemodialysis:new pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease. Kidney Int.2019;95:296-309. PMID:30665570.

 

3 Nijst P, et al. The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol. 2015;65:378-388. PMID:25634838.

 

4 Karg MV, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content:a randomised controlled trial. Cardiovasc Diabetol. 2018;17:5. PMID:29301520.

 

P.76 掲載の参考文献

1 Palmer BF, et al. Extrarenal Effects of Aldosterone on Potassium Homeostasis. Kidney360. 2022;3:561-568. PMID:35582177.

 

P.78 掲載の参考文献

1 Wei KY, et al. Dietary potassium and the kidney:lifesaving physiology. Clin Kidney J. 2020;13:952-968. PMID:33391739.

 

2 柴田茂. 尿細管研究の進歩と高血圧診療への新展開. 日腎会誌. 2022;64:356-361.

 

3 向山政志. 高血圧研究と診療における最近の話題. 日腎会誌. 2022;64:352-355.

 

P.79 掲載の参考文献

1 柴田茂. 尿細管研究の進歩と高血圧診療への新展開. 日腎会誌. 2022;64:356-361.

 

2 Wei KY, et al. Dietary potassium and the kidney:lifesaving physiology. Clin Kidney J. 2020;13:952-968. PMID:33391739.

 

P.81 掲載の参考文献

1 Castaneda-Bueno M. et al. Blood pressure effects of sodium transport along the distal nephron. Kidney Int. 2022;102:1247-1258. PMID:36228680.

 

P.84 掲載の参考文献

1 Schmitz PG. Clinical implications of renal physiology. Chapter 7. The loop of Henle. Learning Innovations, LLC, 2017.

 

2 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

P.86 掲載の参考文献

1 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

2 Seifer JL, Teaching renal physiology at the bedside. Nephrology Self-Assessment Program. 2022;20:67-73.

 

P.88 掲載の参考文献

1 Lederer E, et al. Disorders of fluid and electrolyte balance. Chapter 89. in Hazzard's Geriatric Medicine and Gerontology. 7th edition. McGraw-Hill Education, 2017.

 

2 Miller M. Fluid balance disorders in elderly. Chapter 17. in Online Curricula:Geriatric Nephrology. https://www.asn-online.org/education/distancelearning/curricula/geriatrics/

 

3 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社, 2019.

 

第4章 電解質異常

P.92 掲載の参考文献

1 Chauhan K, et al. Rate of Correction of Hypernatremia and Health Outcomes in Critically Ill Patients. Clin J Am Soc Nephrol. 2019;14:656-663. PMID:30948456.

 

2 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社,2019.

 

P.96 掲載の参考文献

1 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社,2019.

 

2 Preston RA. Acid-Base, Fluids, and Electrolytes Made Ridiculously Simple. edition 3. Medmaster Inc., 2018.

 

3 Gankam Kengne F, et al. Hyponatremia and the Brain. Kid Int Rep. 2017;3:24-35. PMID29340311.

 

P.99 掲載の参考文献

1 Decaux G, et al. Low-solute intake in chronic asymptomatic hyponatraemia related to syndrome of inappropriate secretion of ADH(SIADH):think about food beyond water intake! Nephrol DialTransplant. 2020;35:2013-2014. PMID:32761046.

 

2 山田安希ら. 少量短期間vaptan製剤の投与による低Na血症の補正により, 早期手術が可能であった一例. 日本プライマリ・ケア連合学会誌. 2023;46:20-24.

 

3 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

P.101 掲載の参考文献

1 Decaux G, et al. Low-solute intake in chronic asymptomatic hyponatraemia related to syndrome of inappropriate secretion of ADH(SIADH):think about food beyond water intake! Nephrol Dial Transplant. 2020;35:2013-2014. PMID:32761046.

 

2 山田安希ら. 少量短期間vaptan製剤の投与による低Na血症の補正により, 早期手術が可能であった一例. 日本プライマリ・ケア連合学会誌. 2023;46:20-24.

 

P.104 掲載の参考文献

1 Garrahy A, et al. Hyponatremia and Glucocorticoid Deficiency. in Disorders of Fluid and Electrolyte Metabolism:Focus on Hyponatremia. Karger, 2019.

 

2 Takei M, et al. Five cases of severe hyponatremia in the elderly successfully treated with low doses of hydrocortisone. Geriatr Gerontol Int. 2009;9:391-394. PMID:20002759.

 

P.107 掲載の参考文献

1 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社, 2019.

 

2 Kamel S, et al. Fluid, Electrolyte and Acid-Base Physiology:A Problem-Based Approach. 5th edition. Elsevier, 2016.

 

P.109 掲載の参考文献

1 Palmer BF, et al. Extrarenal Effects of Aldosterone on Potassium Homeostasis. Kidney360. 2022;3:561-568. PMID:35582177.

 

2 St-Jules DE, et al. Etiology-based dietary approach for managing hyperkalemia in people with chronic kidney disease. Nutr Rev. 2022;80:2198-2205. PMID:35482610.

 

慢性の痛み講座 北原先生の痛み塾. https://www.youtube.com/@kitahara_itamijuku

 

P.111 掲載の参考文献

1 Negussie AB, et al. Colonic Fluid and Electrolyte Transport 2022:An Update. Cells. 2022;11:1712. PMID:35626748.

 

2 Palmer BF, et al. Extrarenal Effects of Aldosterone on Potassium Homeostasis. Kidney360. 2022;3:561-568. PMID:35582177.

 

3 Rajendran VM, et al. Colonic Potassium Absorption and Secretion in Health and Disease. Compr Physiol. 2018;8:1513-1536. PMID:30215859.

 

4 Sumida K, et al. Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. J Am Soc Nephrol. 2021;32:950-959. PMID:33547216.

 

P.113 掲載の参考文献

1 Lerma EG. Novel oral potassium binders. Kindey News. 2021;13:13-14.

 

2 Spinowitz BS, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia:A 12-Month Phase 3 Study. Clin J Am Soc Nephrol. 2019;14:798-809. PMID:31110051.

 

3 St-Jules DE, et al. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale. Clin J Am Soc Nephrol. 2022;17:467-472. PMID:34670798.

 

P.116 掲載の参考文献

1 Joshi S, et al. Plant-Based Diets for Kidney Disease:A Guide for Clinicians. Am J Kidney Dis. 2021;77:287-296. PMID:33075387.

 

2 Nicola LD, et al. Recommendations on nutritional intake of potassium in ckd:it's now time to be more flexible! Kidney Int. 2022;102:700-703.

 

3 Agarwal R. Should we liberalize potassium intake in CKD? No, we should not. Kidney Int. 2022;102:703-706. PMID:36150764.

PubMed

4 St-Jules DE, et al. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale. Clin J Am Soc Nephrol. 2022;17:467-472. PMID:34670798.

 

5 Gritter M, et al. Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD. J Am Soc Nephrol. 2022;33:1779-1789. PMID:35609996.

 

6 Ikizler TA, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD:2020 Update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-S107. PMID:32829751.

 

P.119 掲載の参考文献

1 Walker MD, et al. Hypercalcemia:A Review. JAMA. 2022;328:1624-1636. PMID:36282253.

 

2 Zagzag J, et al. Hypercalcemia and cancer:Differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377-386. PMID:30240520.

 

3 深川雅史ら. 図解 水・電解質テキスト 一般検査からきわめる診断・治療のアプローチ. 文光堂, 2006.

 

4 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社, 2019.

 

P.121 掲載の参考文献

1 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社, 2019.

 

P.129 掲載の参考文献

1 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社,2019.

 

2 Reilly RF, et al. Lange Instant Access Acid-Base, Fluids, and Electrolytes. McGraw-Hill Education, 2007.

 

3 Yamada A, et al. A Case of Non-occlusive Mesenteric Ischemia with Significant Hyperphosphatemia. Intern Med. 2023;62:729-732. PMID:35908963.

 

P.133 掲載の参考文献

1 Lerma EV, et al. Nephrology Secrets. 4th edition. Elsevier, 2018.

 

2 Sakaguchi Y, et al. A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD. J Am Soc Nephrol. 2019;30:1073-1085. PMID:31036759.

 

3 Mohanasundaram S. Can SGLT2 Inhibitors be Used in the Treatment of Hypomagnesemia? Renal Fellow Network, 2022/8/16. https://www.renalfellow.org/2022/08/16/can-sglt2-inhibitors-be-used-in-the-treatment-of-hypomagnesemia/

 

4 杉本俊郎. 詳述! 学べる・使える 水・電解質・酸塩基平衡異常Q & A事典. 日本医事新報社, 2019.

 

P.136 掲載の参考文献

1 Martin L. All You Really Need to Know to Interpret Arterial Blood Gases. 2nd edition. Lippincott Williams & Wilkins, 1999.

 

2 DuBose TD. Chapter 51:Acidosis and Alkalosis. in Harrison's Principles of Internal Medicine. 20th edition. McGraw-Hill Education, 2018.

 

3 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

P.138 掲載の参考文献

1 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

P.141 掲載の参考文献

1 Kraut JA. Treatment metabolic acidosis:Controversies and challenges. Nephrology Self-Assessment Program. 2015, 14:1-6.

 

2 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

3 Touron M, et al. Effect of sodium bicarbonate on functional outcome in patients with out-of-hospital cardiac arrest:a post-hoc analysis of a French and North-American dataset. Eur J Emerg Med. 2022;29:210-220. PMID:35297385.

 

4 日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン2018. 東京医学社, 2018.

 

5 Kajimoto S, et al. Modulation of the Association of Hypobicarbonatemia and Incident Kidney Failure With Replacement Therapy by Venous pH:A Cohort Study. Am J Kidney Dis. 2021;77:35-43. PMID:32828983.

 

P.145 掲載の参考文献

1 杉本俊郎. 代謝性アルカローシス. 日内会誌. 2022;111:941-948 .

 

2 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

P.147 掲載の参考文献

1 杉本俊郎. きどにゃんとゆく! 水・電解質を学ぶ旅 腎生理がわかれば, 水・電解質異常がわかる! 南山堂, 2018.

 

Albakr RB, et al. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia:A Review of the Evidence From Clinical Trials. Am J Kidney Dis. 2023;S0272-6386(23)00743-6. PMID:37517546.

 

P.148 掲載の参考文献

Standing corrected? New examination of the rate of correcting hyponatremia. #NephJC. October 24, 2023. https://www.nephjc.com/news/hyponatremia-correction

 

第5章 輸液療法

P.152 掲載の参考文献

1 加藤宏樹. 小児輸液のトリセツ. 金原出版, 2022.

 

2 Seifer JL, Teaching renal physiology at the bedside. Nephrology Self-Assessment Program. 2021;20:67-73.

 

3 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

4 Kamel SK, et al. Fluid, Electrolyte, and Acid-Base Physiology. 5th edition. Elsevier, 2016(ebook, 2017).

 

P.153 掲載の参考文献

1 今井直彦. 極論で語る腎臓内科. 第2版. 丸善出版, 2022.

 

P.156 掲載の参考文献

1 Argaiz ER, et al. Fluid management in acute kidney injury:from evaluating fluid responsiveness towards assessment of fluid tolerance. Eur Heart J Acute Cardiovasc Care. 2022;11:786-793. PMID:36069621.

 

2 Diaz-Gomez JL, et al. Point-of-Care Ultrasonography. N Engl J Med. 2021;385:1593-1602. PMID:34670045.

 

P.158 掲載の参考文献

1 太田啓介. Less is More 考える集中治療. 金芳堂, 2021.

 

2 Ostermann M, et al. Fluid Management in Acute Kidney Injury. Chest. 2019;156:594-603. PMID:31002784.

 

3 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020.

 

P.160 掲載の参考文献

1 日本集中治療学会編. 日本版敗血症ガイドライン2020. 日集中医誌, 2021;28(Supplement).

 

2 Silversides JA, et al. Liberal versus restrictive fluid therapy in critically ill patients. Intensive Care Med. 2019;45:1440-1442. PMID:31399779.

 

3 Xu F, et al. Early initiation of norepinephrine in patients with septic shock:A propensity score-based analysis. Am J Emerg Med. 2022;54:287-296. PMID:35227959.

 

4 太田啓介. Less is More 考える集中治療. 金芳堂, 2021.

 

P.162 掲載の参考文献

1 Forsmark CE, et al. Acute Pancreatitis. N Engl J Med. 2016;375:1972-1981. PMID:27959604.

 

2 Crosignani A, et al. Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit:a narrative review. Ann Intensive Care. 2022;12:98. PMID:36251136.

 

3 de-Madaria E, et al. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis. N Engl J Med. 2022;387:989-1000. PMID:36103415.

 

P.164 掲載の参考文献

Packer M, et al. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. Circulation. 2023;148:1011-1022. PMID:37621153.

PubMed

第6章 利尿薬

P.167 掲載の参考文献

1 Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol. 2019;14:1248-1257. PMID:30936153.

 

2 Mullens W, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387:1185-1195. PMID:36027559.

 

P.169 掲載の参考文献

1 Cox ZL, et al. Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. Kidney360;2022, 3:954-967. PMID:36128483.

 

2 Felker GM, et al. Diuretic Therapy for Patients With Heart Failure:JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:1178-1195. PMID:32164892.

 

3 Rao VS, et al. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. J Am Coll Cardiol. 2021;77:695-708. PMID:33573739.

 

P.171 掲載の参考文献

1 McMahon BA, et al. The furosemide stress test:current use and future potential. Ren Fail. 2021;43:830-839. PMID:33971784.

 

2 Wettersten N, et al. Diuretic Resistance-A Key to Identifying Clinically Significant Worsening Renal Function in Heart Failure? Mayo Clin Proc. 2022;97:1598-1600. PMID:36058571.

 

3 Patschan D, et al. Loop Diuretics in Acute Kidney Injury Prevention, Therapy, and Risk Stratification. Kidney Blood Press Res. 2019;44:457-464. PMID:31362295.

 

P.177 掲載の参考文献

1 Novak JE, et al. Diuretics in States of Volume Overload:Core Curriculum 2022. Am J Kidney Dis. 2022;80:264-276. PMID:35190215.

 

2 Felker GM, et al. Diuretic Therapy for Patients With Heart Failure:JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:1178-1195. PMID:32164892.

 

3 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

4 Packer M, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction:EMPEROR-Preserved Trial. Circulation. 2021;144:1284-1294. PMID:34459213.

 

P.179 掲載の参考文献

1 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022.

 

急性期のうっ血解除に影響を与える2試験. m3.com. 2023年9月17日. https://www.m3.com/clinical/news/1163749

 

P.182 掲載の参考文献

1 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン2019. 日本高血圧学会, 2019. https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf

 

2 Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol. 2019;14:1248-1257. PMID:30936153.

 

3 Agarwal R, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021;385:2507-2519. PMID:34739197.

 

杉本俊郎. きどにゃんとゆく! 酸塩基平衡を学ぶ旅 腎生理がわかれば, 酸塩基平衡もわかる! 南山堂. 2021.

 

P.186 掲載の参考文献

1 AKI(急性腎障害)診療ガイドライン作成委員会編. AKI(急性腎障害)診療ガイドライン2016. 日腎会誌. 2017;59:419-533.

 

2 Patel S, et al. Sepsis Management for the Nephrologist. Clin J Am Soc Nephrol. 2022;17:880-889. PMID:35551069.

 

3 Ostermann M, et al. Fluid Management in Acute Kidney Injury. Chest. 2019;156:594-603. PMID:31002784.

 

4 McMahon BA, et al. The furosemide stress test:current use and future potential. Ren Fail. 2021;43:830-839. PMID:33971784.

 

5 Patschan D, et al. Loop Diuretics in Acute Kidney Injury Prevention, Therapy, and Risk Stratification. Kidney Blood Press Res. 2019;44:457-464. PMID:31362295.

 

6 杉本俊郎. もう困らない外来・病棟での腎臓のみかた. 中外医学社, 2020, pp.70-76.

 

7 杉本俊郎. わかる・つかえる・レベルアップ 賢者の利尿薬. 南山堂, 2022, pp.68-77.

 

書評を投稿する